Stoke Therapeutics Inc. Common Stock (STOK)
Stock · NASDAQ · Health Care
$24.2as of 10/16/2026
Price chart
Active signals
STOK Signal Track Record
How signals performed across all stocks →What STOK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | -2.9% | 45% | September 30, 2026 |
| Bollinger Band Breakout | 34 | +1.3% | 50% | August 7, 2026 |
| Bollinger Band Breakdown | 16 | +5.0% | 56% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -6.0% | 42% | August 20, 2026 |
| Any 20-session window (baseline) | +1.0% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About STOK
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of au…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 170
- Website
- www.stoketherapeutics.com/
Fundamentals
- 1-day range
- $23.64$24.59
- Market cap
- $2.06B
- P/E (trailing)
- —
- P/E (forward)
- -6.85
- EPS (trailing)
- $-3.36
- Dividend yield
- —
- Beta
- 1.36
- Avg. volume
- 869.4K
How Stoke Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 16, 2026 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Stoke Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- STOKStoke Therapeutics Inc. Common Stock$24.17▼ 1.79%Market cap $2.06BP/E —$20.32$40.22
- HCMHUTCHMED (China) Limited American Depositary Shares$14.05▲ 0.79%Market cap $2.06BP/E 133.15$15.57$26
- ZBIOZenas BioPharma Inc. Common Stock$24.84▼ 2.20%Market cap $2.03BP/E —$13.5$44.6
- AUPHAurinia Pharmaceuticals Inc Ordinary Shares$16.51▼ 1.31%Market cap $2.10BP/E 7.11$11.21$19.25
- GHRSGH Research PLC Ordinary Shares$18.15▼ 3.51%Market cap $2.10BP/E —$12.04$31.44
- NUVBNuvation Bio Inc. Class A Common Stock$4.45▼ 6.32%Market cap $2.13BP/E —$3.36$9.75
- BHVNBiohaven Ltd. Common Shares$10.78▼ 5.69%Market cap $2.17BP/E —$7.48$18.57
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| STOK Stoke Therapeutics Inc. Common Stock | $2.06B | — | $24.17 | ▼ 1.79% | $20.32$40.22 |
| HCM HUTCHMED (China) Limited American Depositary Shares | $2.06B | 133.15 | $14.05 | ▲ 0.79% | $15.57$26 |
| ZBIO Zenas BioPharma Inc. Common Stock | $2.03B | — | $24.84 | ▼ 2.20% | $13.5$44.6 |
| AUPH Aurinia Pharmaceuticals Inc Ordinary Shares | $2.10B | 7.11 | $16.51 | ▼ 1.31% | $11.21$19.25 |
| GHRS GH Research PLC Ordinary Shares | $2.10B | — | $18.15 | ▼ 3.51% | $12.04$31.44 |
| NUVB Nuvation Bio Inc. Class A Common Stock | $2.13B | — | $4.45 | ▼ 6.32% | $3.36$9.75 |
| BHVN Biohaven Ltd. Common Shares | $2.17B | — | $10.78 | ▼ 5.69% | $7.48$18.57 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Stoke Therapeutics Presents Data For STK-002 Supporting Disease-Modifying Potential In Autosomal Dominant Optic Atrophy At AAO 2026 Annual Meetingbenzinga · 10/12/2026
- FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)Yahoo · 10/9/2026
- Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual MeetingYahoo · 10/6/2026
- Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet SyndromeYahoo · 10/5/2026
- Government Study: Cellphone Radiation Linked To CancerBenzinga · 10/5/2026
- Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and CommercializationYahoo · 9/23/2026
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Yahoo · 9/16/2026
Insider Activity
Insider Actions →- Jonathan Allan · October 2, 2026 · Sale627 @ $26.33
- Barry Ticho · October 1, 2026 · Sale1.1K @ $26.16
- Cumbo Alexander · September 23, 2026 · Grant39.7K
- Barry Ticho · September 1, 2026 · Sale1.6K @ $31.06
- Barry Ticho · September 1, 2026 · Sale3.9K @ $30.51
- Jonathan Allan · August 18, 2026 · Sale2.7K @ $32.01
- Barry Ticho · August 18, 2026 · Sale242 @ $32.47
- Barry Ticho · August 18, 2026 · Sale4.5K @ $32.01
- Edward M. Kaye, MD · August 18, 2026 · Sale637 @ $32.47
- Edward M. Kaye, MD · August 18, 2026 · Sale11.9K @ $32.01
- Jonathan Allan · August 18, 2026 · Sale145 @ $32.47
- Jonathan Allan · August 14, 2026 · Option Exercise6.0K
- Barry Ticho · August 14, 2026 · Option Exercise10.0K
- Edward M. Kaye, MD · August 14, 2026 · Option Exercise26.3K
- Barry Ticho · August 3, 2026 · Sale1.3K @ $29.45
Institutional Ownership
March 31, 2026
- Total shares held
- 70.34M
- Total value held
- $2.22B
- Institutional holders
- 191
- Unknown5.62M
- Unknown5.39M
- Unknown5.38M
- Unknown4.76M
- Unknown4.16M
- Unknown3.42M
- Unknown3.34M
- Unknown3.17M
- Unknown3.10M
- Unknown2.55M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting
Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting. Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.